JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ISRG

487.26

+2.36%↑

DHR

216.47

+0.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ISRG

487.26

+2.36%↑

DHR

216.47

+0.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ISRG

487.26

+2.36%↑

DHR

216.47

+0.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ISRG

487.26

+2.36%↑

DHR

216.47

+0.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ISRG

487.26

+2.36%↑

DHR

216.47

+0.36%↑

Search

Abbott Laboratories

Geschlossen

BrancheGesundheitswesen

110.82 1.61

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

110.08

Max

111.03

Schlüsselkennzahlen

By Trading Economics

Einkommen

-135M

1.6B

Verkäufe

90M

11B

KGV

Branchendurchschnitt

29.411

84.243

EPS

1.5

Dividendenrendite

2.2

Gewinnspanne

14.46

Angestellte

115,000

EBITDA

-491M

2.5B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+25.2% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

2.20%

2.28%

Nächstes Ergebnis

15. Apr. 2026

Nächste Dividendenausschüttung

13. Feb. 2026

Nächstes Ex-Dividendendatum

14. Apr. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-21B

190B

Vorheriger Eröffnungskurs

109.21

Vorheriger Schlusskurs

110.82

Nachrichtenstimmung

By Acuity

30%

70%

73 / 352 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Abbott Laboratories Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Jan. 2026, 18:36 UTC

Ergebnisse
Wichtige Markttreiber

Abbott Laboratories Raised Prices, Prompting Sales Slump -- Update

22. Jan. 2026, 13:23 UTC

Ergebnisse
Wichtige Markttreiber

Abbott Laboratories 4Q Sales Grow, Outlook Underwhelms

20. Nov. 2025, 13:14 UTC

Akquisitionen, Fusionen, Übernahmen

Correction to Abbott to Acquire Exact Sciences for $21 Billion Article

20. Nov. 2025, 13:11 UTC

Akquisitionen, Fusionen, Übernahmen

Abbott to Acquire Exact Sciences for $21 Billion -- Update

28. Jan. 2026, 14:48 UTC

Ergebnisse

Abbott Stock Fell the Most in 23 Years After Earnings. The CEO Bought $2 Million of Shares. -- Barrons.com

23. Jan. 2026, 16:59 UTC

Ergebnisse

Correction to Abbott Stock Drops Article on Jan. 22

22. Jan. 2026, 20:42 UTC

Ergebnisse

Abbott Stock Is on Pace for Worst Day Since 2000. The Nutrition Business Is a Drag on Earnings. -- Barrons.com

22. Jan. 2026, 16:19 UTC

Ergebnisse

Abbott Stock Slumps. The Nutrition Business Is a Drag on Earnings. -- Barrons.com

22. Jan. 2026, 15:22 UTC

Ergebnisse

Abbott Stock Drops on Slumping Sales of Baby Formula and Nutrition Shakes -- WSJ

22. Jan. 2026, 14:41 UTC

Heiße Aktien

Stocks to Watch Thursday: Intel, P&G, GE Aerospace -- WSJ

22. Jan. 2026, 14:08 UTC

Market Talk
Ergebnisse

Abbott Posts Disappointing 4Q -- Market Talk

22. Jan. 2026, 12:49 UTC

Ergebnisse

Abbott Stock Slumps on Earnings. What's Weighing on the Medical Device Maker. -- Barrons.com

22. Jan. 2026, 12:31 UTC

Ergebnisse

Abbott Labs: Well Positioned for Accelerating Growth in 2026 >ABT

22. Jan. 2026, 12:30 UTC

Ergebnisse

Abbott Labs Sees 2026 Organic Sales Growth of 6.5%-7.5% >ABT

22. Jan. 2026, 12:30 UTC

Ergebnisse

Abbott Labs Sees 1Q Adj EPS $1.12-Adj EPS $1.18 >ABT

22. Jan. 2026, 12:30 UTC

Ergebnisse

Abbott Labs 4Q Net $1.78B >ABT

22. Jan. 2026, 12:30 UTC

Ergebnisse

Abbott Labs 4Q Sales $11.46B >ABT

22. Jan. 2026, 12:30 UTC

Ergebnisse

Abbott Labs Sees FY Adj EPS $5.55-Adj EPS $5.80 >ABT

22. Jan. 2026, 12:30 UTC

Ergebnisse

Abbott Labs 4Q Organic Sales Growth Up 3.0% >ABT

22. Jan. 2026, 12:30 UTC

Ergebnisse

Abbott Labs 4Q Adj EPS $1.50 >ABT

22. Jan. 2026, 12:30 UTC

Ergebnisse

Abbott Labs 4Q EPS $1.01 >ABT

20. Nov. 2025, 21:23 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

20. Nov. 2025, 16:51 UTC

Akquisitionen, Fusionen, Übernahmen

Abbott Laboratories Will Buy Cologuard Maker Exact Sciences for $21 Billion -- Barrons.com

20. Nov. 2025, 15:08 UTC

Akquisitionen, Fusionen, Übernahmen

Abbott to Acquire Exact Sciences for $21 Billion -- 4th Update

20. Nov. 2025, 14:39 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Abbott and Exact Sciences Should Make a Good Fit -- Market Talk

20. Nov. 2025, 14:30 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Exact Sciences Should Give Abbott's Diagnostics Business a Needed Boost -- Market Talk

20. Nov. 2025, 13:54 UTC

Akquisitionen, Fusionen, Übernahmen

These Stocks Are Moving the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Palo Alto Networks, Alphabet, and More -- Barrons.com

20. Nov. 2025, 13:51 UTC

Akquisitionen, Fusionen, Übernahmen

Abbott to Acquire Exact Sciences for $21 Billion -- 3rd Update

20. Nov. 2025, 13:25 UTC

Akquisitionen, Fusionen, Übernahmen

Abbott to Acquire Exact Sciences for $21 Billion -- 2nd Update

20. Nov. 2025, 13:24 UTC

Akquisitionen, Fusionen, Übernahmen

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion. -- Barrons.com

Peer-Vergleich

Kursveränderung

Abbott Laboratories Prognose

Kursziel

By TipRanks

25.2% Vorteil

12-Monats-Prognose

Durchschnitt 138.76 USD  25.2%

Hoch 158 USD

Tief 122 USD

Basierend auf 18 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Abbott Laboratories – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

18 ratings

17

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

132.82 / 134.43Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Neutral Evidence

Langfristig

Bullish Evidence

Stimmung

By Acuity

73 / 352 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
help-icon Live chat